title: A viewpoint on European Medicines Agency experience with investigational medicinal products for Ebola.
authors.affiliation: Office of Anti-Infectives and Vaccines, European Medicines Agency, London, UK.
authors.forename: Marco
authors.initials: M
authors.lastname: Cavaleri
authors.affiliation: Office of Biostatistics and Methodology Support, European Medicines Agency, London, UK.
authors.forename: Andrew
authors.initials: A
authors.lastname: Thomson
authors.affiliation: Medical Products Agency, Uppsala, Sweden.
authors.forename: Tomas
authors.initials: T
authors.lastname: Salmonson
authors.affiliation: Medicines & Healthcare products Regulatory Agency, London, UK Rob.Hemmings@mhra.gsi.gov.uk.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Hemmings
mesh_terms: D000354:Africa, Western / Q000453:epidemiology; D000998:Antiviral Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods*; D004196:Disease Outbreaks; D017277:Drug Approval / Q000379:methods / Q000458:organization & administration*; D015507:Drugs, Investigational / Q000627:therapeutic use*; D046129:Ebola Vaccines; D005060:Europe; D019142:Hemorrhagic Fever, Ebola / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D014944:World Health Organization
chemical_list: D000998:Antiviral Agents; D015507:Drugs, Investigational; D046129:Ebola Vaccines